{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008825","form_type":"8-K","ticker":"AZTA","cik":"0000933974","company_name":"Azenta, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.925005+00:00","generated_at":"2026-06-15T11:38:28.713181+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Azenta Q2 FY23 revenue $148M, GAAP EPS loss $0.03, guided Q3 below consensus","bullets":["Revenue $148M (+2% YoY; -17% sequentially); non-GAAP diluted EPS ($0.06) vs $0.12 a year ago.","Life Sciences Products revenue $59M (+10% YoY) but B Medical $15M, below expectations due to order delays.","Adjusted EBITDA ($2.4M) vs $19M prior year; expects $15M annual cost savings from realignment.","Realigns into three groups (Multi-Omics, Sample Management, B Medical) effective Oct 1, 2023.","Q3 FY23 guidance: revenue $150-168M; non-GAAP EPS ($0.07)-$0.03; GAAP EPS ($0.29)-($0.19)."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008825","json":"https://secwatch.observer/filing/0001558370-23-008825.json","markdown":"https://secwatch.observer/filing/0001558370-23-008825.md","text":"https://secwatch.observer/filing/0001558370-23-008825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/933974/000155837023008825/0001558370-23-008825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/933974/000155837023008825/azta-20230509x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T11:38:28.713181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"38317c622321b502c766ac24eaea1edb3067f97b","claim":"Azenta, Inc. reported financial results for the second quarter ended March 31, 2023.","evidence_excerpt":"On May 9, 2023, Azenta, Inc. (“Azenta” or the “Company”) announced via press release its financial results for the fiscal quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/933974/000155837023008825/0001558370-23-008825-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}